Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

The NRF2-LOC344887 signaling axis suppresses pulmonary fibrosis

Redox Biology(2020)10.1016/j.redox.2020.101766Source: DataRank Database

The NRF2-LOC344887 signaling axis suppresses pulmonary fibrosis is a research paper published in Redox Biology (2020). On theSindex it has a DataRank of 0. It has been cited 78 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access78 citations

Download PDF

Cite:

Linked data & code

nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (12 grants)Impact (FWCI 4.09)OA: goldTopics (48)Linked Datasets (25)DataCite Reuse (25)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (10)

Gang Luo ORCID,Matthew Dodson ORCID,Cody J. Schmidlin ORCID,Yongyi Wei ORCID,Barış Kerimoğlu ORCID

Live enrichment

PubMed:33126057 PMC:PMC7573654 OpenAlex:https://openalex.org/W3094306359

NCI NIH HHS

Grant: R01 CA226920

NIEHS NIH HHS

Grant: P30 ES006694

NIEHS NIH HHS

Grant: R35 ES031575

NIEHS NIH HHS

Grant: T32 ES007091

NHLBI NIH HHS

Grant: R01 HL141387

NHLBI NIH HHS

Grant: R42 HL152888

NHLBI NIH HHS

Grant: P01 HL126609

NHLBI NIH HHS

Grant: P01 HL134610

NIDDK NIH HHS

Grant: R01 DK109555

NIEHS NIH HHS

Grant: P42 ES004940

NIEHS NIH HHS

Grant: R01 ES031463

National Institutes of Health

FWCI

4.09

Citation Percentile

1.0%

Citation Trend

2021

2022

2023

2024

2025

2026

goldLicense: cc-by-nc-nd

journalhttps://www.sciencedirect.com/science/article/pii/S221323172030971X/pdf

publisherhttps://www.sciencedirect.com/science/article/pii/S221323172030971X/pdf

publisherhttps://api.elsevier.com/content/article/PII:S221323172030971X?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S221323172030971X?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.redox.2020.101766

Fields of Study

Genomics, phytochemicals, and oxidative stressMicroRNA in disease regulationCircular RNAs in diseasesFibrosisHumansIsothiocyanatesLungMyofibroblastsNF-E2-Related Factor 2Phosphatidylinositol 3-KinasesRNA, Long NoncodingSignal Transduction

MeSH Terms

FibrosisHumansLungSignal TransductionIsothiocyanatesPhosphatidylinositol 3-KinasesNF-E2-Related Factor 2MyofibroblastsRNA, Long Noncoding

Keywords

Downregulation and upregulationGene knockdownCancer researchFibrosisIdiopathic pulmonary fibrosisMyofibroblastPI3K/AKT/mTOR pathwayPulmonary fibrosisSignal transductionTIMP1BiologyCell biologyActivator (genetics)Protein kinase BExtracellular matrixChemistryGeneGene expressionMedicineLungPathologyInternal medicineGeneticsNRF2Pi3k-aktCdh2Loc344887

Sustainable Development Goals

SDG 0: Good health and well-being

Additional file 9 of ROS-responsive liposomes as an inhaled drug delivery nanoplatform for idiopathic pulmonary fibrosis treatment via Nrf2 signaling

10.6084/m9.figshare.19727475.v1figshare

Additional file 9 of ROS-responsive liposomes as an inhaled drug delivery nanoplatform for idiopathic pulmonary fibrosis treatment via Nrf2 signaling

10.6084/m9.figshare.19727475figshare

Additional file 8 of ROS-responsive liposomes as an inhaled drug delivery nanoplatform for idiopathic pulmonary fibrosis treatment via Nrf2 signaling

10.6084/m9.figshare.19727472.v1figshare

Additional file 8 of ROS-responsive liposomes as an inhaled drug delivery nanoplatform for idiopathic pulmonary fibrosis treatment via Nrf2 signaling

10.6084/m9.figshare.19727472figshare

Additional file 7 of ROS-responsive liposomes as an inhaled drug delivery nanoplatform for idiopathic pulmonary fibrosis treatment via Nrf2 signaling

10.6084/m9.figshare.19727469.v1figshare

Additional file 7 of ROS-responsive liposomes as an inhaled drug delivery nanoplatform for idiopathic pulmonary fibrosis treatment via Nrf2 signaling

10.6084/m9.figshare.19727469figshare

Additional file 6 of ROS-responsive liposomes as an inhaled drug delivery nanoplatform for idiopathic pulmonary fibrosis treatment via Nrf2 signaling

10.6084/m9.figshare.19727466.v1figshare

Additional file 6 of ROS-responsive liposomes as an inhaled drug delivery nanoplatform for idiopathic pulmonary fibrosis treatment via Nrf2 signaling

10.6084/m9.figshare.19727466figshare

Additional file 5 of ROS-responsive liposomes as an inhaled drug delivery nanoplatform for idiopathic pulmonary fibrosis treatment via Nrf2 signaling

10.6084/m9.figshare.19727463.v1figshare

Additional file 5 of ROS-responsive liposomes as an inhaled drug delivery nanoplatform for idiopathic pulmonary fibrosis treatment via Nrf2 signaling

10.6084/m9.figshare.19727463figshare

Additional file 4 of ROS-responsive liposomes as an inhaled drug delivery nanoplatform for idiopathic pulmonary fibrosis treatment via Nrf2 signaling

10.6084/m9.figshare.19727460.v1figshare

Additional file 4 of ROS-responsive liposomes as an inhaled drug delivery nanoplatform for idiopathic pulmonary fibrosis treatment via Nrf2 signaling

10.6084/m9.figshare.19727460figshare

Additional file 3 of ROS-responsive liposomes as an inhaled drug delivery nanoplatform for idiopathic pulmonary fibrosis treatment via Nrf2 signaling

10.6084/m9.figshare.19727457.v1figshare

Additional file 3 of ROS-responsive liposomes as an inhaled drug delivery nanoplatform for idiopathic pulmonary fibrosis treatment via Nrf2 signaling

10.6084/m9.figshare.19727457figshare

Additional file 2 of ROS-responsive liposomes as an inhaled drug delivery nanoplatform for idiopathic pulmonary fibrosis treatment via Nrf2 signaling

10.6084/m9.figshare.19727454.v1figshare

Additional file 2 of ROS-responsive liposomes as an inhaled drug delivery nanoplatform for idiopathic pulmonary fibrosis treatment via Nrf2 signaling

10.6084/m9.figshare.19727454figshare

Additional file 1 of ROS-responsive liposomes as an inhaled drug delivery nanoplatform for idiopathic pulmonary fibrosis treatment via Nrf2 signaling

10.6084/m9.figshare.19727451.v1figshare

Additional file 1 of ROS-responsive liposomes as an inhaled drug delivery nanoplatform for idiopathic pulmonary fibrosis treatment via Nrf2 signaling

10.6084/m9.figshare.19727451figshare

Additional file 16 of ROS-responsive liposomes as an inhaled drug delivery nanoplatform for idiopathic pulmonary fibrosis treatment via Nrf2 signaling

10.6084/m9.figshare.19727448.v1figshare

Additional file 16 of ROS-responsive liposomes as an inhaled drug delivery nanoplatform for idiopathic pulmonary fibrosis treatment via Nrf2 signaling

10.6084/m9.figshare.19727448figshare

The NRF2-LOC344887 signaling axis suppresses pulmonary fibrosis

FAIR Checklist

Authors (10)

Funding (12 grants)

Impact

Open Access

Topics

Linked Datasets (25)

Annotations (Europe PMC)